Results from a Phase 3 trial by Sanofi-aventis have shown that the investigational compound, cabazitaxel, and prednisone/prednisolone markedly enhanced overall and progression-free survival in patients with metastatic hormone-refractory prostate cancer where the disease advanced after treatment with docetaxel-based chemotherapy.
Results from a phase 3 trial by Sanofi-aventis have shown that the investigational compound, cabazitaxel, plus prednisone/prednisolone markedly enhanced overall and progression-free survival in patients with metastatic hormone-refractory prostate cancer in which the disease advanced after treatment with docetaxel-based chemotherapy.
In the multicenter, randomized TROPIC trial, conducted across 26 countries including the United States, researchers compared the combined treatment of cabazitaxel plus prednisone/prednisolone with mitoxantrone plus prednisone/prednisolone for a total of 755 patients with metastatic hormone-refractory prostate cancer.
“Improved overall survival was demonstrated in this trial – and these are the first data to show a statistical improvement in overall survival in patients with this difficult-to-treat and aggressive form of prostate cancer,” said Oliver Sartor, MD, Plitz Professor for Cancer Research,Tulane Medical School, New Orleans.
The trial was intended to evaluate those with metastatic hormone-refractory prostate cancer whose disease had advanced after treatment with docetaxel-based chemotherapy. Risk of death was reduced by 30% [HR=0.70; 95% CI, 0.59–0.83; P.0001] as a result of the combination of cabazitaxel and prednisone/prednisolone with a clinically meaningful median overall survival of 15.1 months in the cabazitaxel combination arm, compared with 12.7 months in the mitoxantrone combination arm.
The most frequent grade 3/4 hematological adverse events with cabazitaxel were neutropenia (81.7%), febrile neutropenia (7.5%), and infections (10.2%); frequent grade 3/4 non-hematological adverse events are nausea (1.9%), vomiting (1.9%), and diarrhea (6.2%). Deaths associated with adverse events were 4.9% for those treated with cabazitaxel, compared with 1.9% for those taking mitoxantrone.
FDA Issues Complete Response for High-Dose Opioid Rescue Med
July 16th 2024OX124 is a nasal spray provides rapid absorption of naloxone for patients experiencing an opioid overdose. The FDA would like to see additional technical data, as well as data on whether patients can correctly use the device.
Read More